Trial Profile

A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Characteristics and Initial Anti-tumor Activity of IPG1094 in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 05 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IPG 1094 (Primary)
Indications Glioma; Head and neck cancer; Male breast cancer; Malignant melanoma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions
Sponsors Immunophage Biotech

27 Apr 2025 Planned End Date changed from 15 Aug 2024 to 9 Jul 2027.
27 Apr 2025 Planned primary completion date changed from 15 Jul 2024 to 9 Jul 2027.
27 Apr 2025 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com